0001829126-26-003906
SEC filingPicard Medical, Inc. is a medical technology company that manufactures and sells the FDA-approved SynCardia Total Artificial Heart as a bridge-to-transplant for end-stage biventricular heart failure patients. This S-1 registers a $10 million offering of common stock, pre-funded warrants, and common warrants to fund development of next-generation implantable hearts and label expansions.
Picard Medical operates through its subsidiary SynCardia, holding a unique position as the sole provider of an FDA-approved total artificial heart for bridge-to-transplant therapy in end-stage biventricular heart failure patients. With over 2,100 implants across 27 countries since 1985, the SynCardia TAH (50cc/70cc models) replaces both ventricles and valves, powered by external drivers (C2 hospital, Freedom portable), generating pulsatile flow up to 10.5L/min. This differentiates it from LVADs (one ventricle) and ECMO (hospital-bound), enabling hospital discharge. FY2025 revenue grew 13% to $4.9M (96% products, 4% rentals), but gross margins remain negative at -4% due to high manufacturing costs and driver maintenance. Net loss widened to $27M from $21M, driven by $13.7M other expenses (derivatives, interest on $15M senior secured note). Cash burn was $15.7M operating; post-IPO (Sep 2025, $15.2M net) and note, cash stands at $7.5M with $11.5M total liquidity, but going concern warning persists amid ongoing losses and development needs.
The $10M offering (11.8M shares/warrants at $0.846/share, NYSE American PMI) follows rapid post-IPO dilution: shares outstanding rose from ~9.3M (Dec 2024) to 75.4M (Apr 2026) via $20M+ preferred/note conversions. Proceeds target high-upside R&D: Emperor TAH (fully implantable, animal trials started Nov 2025, FDA ~2029), Unicorn/Freedom+ drivers (FDA 2026-28), label expansions (BTC/long-term support, FDA decision Q3 2026), EU MDR/CE Mark, China NMPA. These address core risks: stagnant U.S. adoption (BTT-only, ~20 active centers), EU MDR lapse (2022), manufacturing bottlenecks (hand-built SPUS ventricles, single Tucson facility, key supplier dependencies like Bimba/Heitek valves). Unit economics pressure: DRG-001 reimburses $187K-$482K/hospital stay, but TAH ASP undisclosed vs LVADs ($120K).
Competition centers on TAHs (Carmat Aeson CE-marked but insolvent; BiVACOR early feasibility) and MCS alternatives (Abbott HeartMate LVADs). Moat: 30+ years data, ISO 13485 manufacturing, CMS coverage. Governance: Hunniwell controls 52.6% (controlled company), CEO Schnegelsberg brings medtech leadership. Risks loom large—execution-dependent R&D, regulatory hurdles (FDA data needs for expansions), customer concentration (few transplant centers), supply chain fragility. Success hinges on Emperor commercialization and international entry amid $27M+ cumulative losses.